STM Article Repository

The primary objective of this case report is to bring awareness among medical professionals regarding the potential cutaneous adverse reactions that may occur during the administration of terbinafine. SJS and TEN are uncommon, severe skin reactions characterized by extensive loss of skin and mucosal tissue, often accompanied by systemic symptoms. In more than 80% of cases, medications are identified as the causative agent for these reactions. SJS-TEN overlap syndrome is a very rare but severe cutaneous adverse drug reaction that is caused by terbinafine administration. We report a case of a 45-year-old female patient, with a documented history of uncontrolled diabetes and currently on medications, Metformin and Glimepiride, was admitted to a tertiary care hospital. The patient was suffering from vulvovaginal infection for which she was consuming terbinafine which led to the occurrence of cutaneous eruptions, across the right and left lower limbs, face, upper limbs, chest, back, arms, and abdomen, affecting almost the entire body covering 10- 30% of the body surface which makes it to fall under the category of SJS-TEN overlap syndrome. Even though terbinafine is thought to be safe, it can cause extremely serious adverse drug reactions, thus while prescribing it, appropriate safety measures must be performed. Patients having a history of drug reactions should not take the medication. The primary objective of this case report is to raise awareness among healthcare professionals about the potential for severe cutaneous drug responses induced by terbinafine and to instill vigilance in them regarding potential risks.